Dynamic Stem Cell Therapy

Warning LetterOpen

Dale Carrison, D.O., FACEP, FACOEP Medical Director Dynamic Stem Cell Therapy 2551 N. Green Valley Parkway Building C, Suite 305C Henderson , NV 89014 United States Contact@stemcellpowernow.comIssued Feb 11, 2026Center for Biologics Evaluation and Research

View Letter

Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy.

Violations6

Issue DateFeb 11, 2026

Product TypeBiologics

StatusOpen

Letter Details

Firm: Dynamic Stem Cell Therapy
Location: Dale Carrison, D.O., FACEP, FACOEP Medical Director Dynamic Stem Cell Therapy 2551 N. Green Valley Parkway Building C, Suite 305C Henderson , NV 89014 United States Contact@stemcellpowernow.com
FEI Number: N/A
Country: United States
Issue Date: February 11, 2026
Issuing Office: Center for Biologics Evaluation and Research
Product Type: Biologics
Status: Open

Summary

Dynamic Stem Cell Therapy was cited for misbranding and marketing an unapproved umbilical cord-derived stem cell product as a drug without FDA licensure or approval. The company made therapeutic claims on its website that their stem cell product could treat sports injuries, cardiovascular disease, arthritis, and provide anti-aging benefits, thereby establishing it as a drug intended to diagnose, cure, mitigate, treat, or prevent disease in humans. These marketing claims violated Section 301(k) of the Federal Food, Drug, and Cosmetic Act by promoting an unlicensed biological product for uses that required FDA approval before distribution in interstate commerce.

Dynamic Stem Cell Therapy FDA Warning Letter, February 11, 2026